Antiproliferative activity in vitro and in vivo of the spicamycin analogue KRN5500 with altered glycoprotein expression in vitro

Clinical Cancer Research

Volumn 3, Issue 3, 1997, Pages 455-463

  Burger, Angelika M ^a   Kaur, Gurmeet ^a   Hollingshead, Melinda ^a   Fischer, Randy T ^c   Nagashima, Kunio ^b   Malspeis, Louis ^a   Duncan, Kimberly L K ^a   Sausville, Edward A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 [4 DEOXY 4 (2,4 TETRADECADIENOYLGLYCYLAMINO) GLYCERO BETA MANNOHEPTOPYRANOSYLAMINO] 9H PURINE; ANTINEOPLASTIC AGENT; NUCLEOSIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN HL 60; COLON CARCINOMA; CONTROLLED STUDY; GLYCOPROTEIN SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL DIVISION; COLONIC NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; FLOW CYTOMETRY; GALANTHUS; GLYCOPROTEINS; HL-60 CELLS; HUMANS; LECTINS; MANNOSE; MEMBRANE GLYCOPROTEINS; MICE; MICE, NUDE; PLANT LECTINS; PURINE NUCLEOSIDES; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0030888689     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Hayakawa, Y.,Nakagawa, M.,Kawai, H.,Tanabe, K.,Nakayama, H.,Shimazu, A.,Seto, H.,and Otake, N. Spicamycin, a new differentiation inducer of mouse myeloid leukemia cells (M1) and human promyelocytic leukemia cells (HL60TB). Agric. Biol. Chem.,49:2685-2691, 1985.
2. Hayakawa, Y.,Nakagawa, M, Kawai, H.,Tanabe, K.,Nakayama, H.,Shimazu, A.,Seto, H.,and Otake, N. Studies on the differentiation inducers of myeloid leukemic cells. III. Spicamycin, a new inducer of differentiation of HL60TB human promyelocytic leukemia cells. J. Antibiot. (Tokyo), 36:934-937, 1983.
3. Kamishohara, M.,Kawa, I. H.,Odagawa, A.,Isoe, T.,Mochizuki, J.,Uchida, T.,Hayakawa, Y.,Seto, H.,Tsuruo, T.,and Otake, N. Structure-antitumor relationship of semi-synthetic spicamycin analogues. J. Antibiot. (Tokyo), 46:1439-1446, 1993.
4. Kamishohara, M.,Kauai, H.,Odagawa, A.,Isoe, T.,Mochizuki, J.,Ucida, T.,Hayakawa, Y.,Seto, H.,Tsuro, T.,and Otake, N. Antitumor activity of SPM VIII, a derivative of the nucleoside antibiotic spicamycin, against human tumor xenografts. J. Antibiot. (Tokyo), 47:1305-1311, 1994.
5. Kamishohara, M.,Kauai, H.,Sakai, T.,Isoe, T, Hasegawa, K.,Mochizuki, J.,Uchida, T.,Kataoka, S.,Yamaki, H.,Tsuro, T.,and Otake, N. Antitumor activity of a spicamycin derivative, KRN5500, and its active metabolism in tumor cells. Oncol. Res.,6: 383-390, 1994.
6. Elbein, A. D. Inhibitors of the biosynthesis and processing of N-linked oligosaccharide chains. Annu. Rev. Biochem., 56: 497-534, 1987.
7. Elbein, A. D. Glycosidase inhibitors: inhibitors of N-linked oligosaccharide processing. FASEB J.,5: 3055-3063, 1991.
8. Goss, P. E.,Baker, M. A.,Carver, J. P.,and Dennis, J. W. Inhibitors of carbohydrate processing: a new class of anti-cancer agents. Clin. Cancer Res.,1: 935-944, 1995.
9. Grever, M. R.,Schepartz, S. A.,and Chabner, B. A. The National Cancer Institute's cancer drug discovery and development program. Semin. Oncol.,19:622-638, 1992.
10. Skehan, P.,Storeng, R.,Scudiero, D.,Monks, A.,McMahon, J.,Vistica, D.,Warren, J. T.,Bokesch, H.,Kenney, S.,and Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst.,82: 1107-1112, 1990.
11. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65: 55-63, 1983.
12. Alley, M. C.,Pacula-Cox, D. M.,Hursey, M. L.,Rubinstein, L. R.,and Boyd, M. R. Morphometric and colorimetric analyses of human tumor cell line growth and drug sensitivity in soft agar culture. Cancer Res.,51:1247-1256, 1991.
13. Alley, M. C.,and Lieber, M. M. Measurement of human tumor cell growth in soft-agar culture using computer-assisted volume analysis. Br. J. Cancer, 52: 205-214, 1985.
14. Kaur, G.,Stetler-Stevenson, M.,Sebers, S.,Worland, P.,Sedlacek, H.,Myers, C.,and Czech, J. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J. Natl. Cancer Inst.,84:1736-1740, 1992.
15. DeLuca, M.,and McElroy, W. D. Purification and properties of firefly luciferase. In:M. A. DeLuca (ed.), Methods in Enzymology, Vol. 57, pp. 3-15. New York: Academic Press, Inc.,1978.
16. Burger, A. M.,Kaur, G.,Alley, M. C.,Supko, J. G.,Malspeis, L.,Grever, M. R.,and Sausville, E. A. Tyrphostin AG17, [(3,5-Di-tertbutyl-4-hydroxybenzylidene)-malononitrile], inhibits cell growth by disrupting mitochondria. Cancer Res.,55: 2794-2799, 1995.
17. Hiraizumi, S.,Spohr, U.,and Spiro, R. G. Characterization of endomannosidase inhibitors and evaluation of their effect on N-linked oligosaccharide processing during glycoprotein biosynthesis. J. Biol. Chem.,268: 9927-9935, 1993.
18. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.), 227: 680-685, 1970.
19. Burnette, W. N. Western blotting: electrophoretic transfer of protein from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibodies and radioiodinated protein A. Anal. Biochem.,112: 195-200, 1981.
20. Ausubel, F. M.,Brent, R.,Kingston, R. E.,Moore, D. D.,Seidman, J. G.,Smith, J. A.,and Struhl, K. Preparation and analysis of glycoconjugates. In:K. Janssen (ed.), Current Protocols in Molecular Biology Vol. 2, pp. 1705-17147. New York: Greene Publishing Associates, 1994.
21. Shibuya, N.,Goldstein, I. J.,Van Damme, E. J. M.,and Peumans, W. J. Binding properties of a mannose-specific lectin from snowdrop (Galanthus nivalis) bulb. J. Biol. Chem.,263:728-734, 1988.
22. Evermann, J. F.,Heeney, J. L.,McKeirnan, A. J.,and O'Brian, S. J. Comparative features of a coronavirus isolated from a cheetah with feline infectious peritonitis. Virus Res.,13:15-28, 1989.
23. Paull, K. D.,Hamel, E.,and Malspeis, L. Prediction of biochemical mechanism of action from the in vitro antitumor screen of the National Cancer Institute. In:W. U. Foye (ed.), Cancer Chemotherapeutic Agents, pp. 9-46. Washington, DC: American Chemical Society, 1995.
24. Tan, A.,van den Brock, L.,van Boeckel, S.,Ploegh, H.,and Bolscher, J. Chemical modification of the glycosidase inhibitor 1-deoxynojirimycin. J. Biol. Chem.,266: 14504-14510, 1991.
25. Saunier, B.,Kilker, R. D.,Tkacz, J. S.,Quaroni, A.,and Herscovics, A. Inhibition of N-linked complex oligosaccharide formation by 1-deoxynojirimycin, an inhibitor of processing glucosidases. J. Biol. Chem.,257: 14155-14161, 1982.
26. Schmitt, J. W.,and Elbein, A. D. Inhibition of protein synthesis also inhibits synthesis of lipid-linked oligosaccharides. J. Biol. Chem.,254:12291-12294, 1979.
27. Lee, Y. S.,Nishio, K.,Ogasawana, H.,Funayama, Y.,Ohira, T.,and Saijo, N. In vitro cytotoxicity of a novel antitumor antibiotic, spicamycin derivative, in human lung cancer cell lines. Cancer Res.,55: 1075-1079, 1995.
28. Elbein, A. D. The tunicamycins - useful tools for studies on glycoproteins. Trends Biochem. Sci.,6:219-221, 1981.